Regeneron’s earnings boosted by demand for blockbuster eye drug Eylea - MarketWatch
1. Regeneron reported Q4 earnings of $8.06 per share, topping expectations. 2. Eylea sales increased 2%, driven by the new Eylea HD formulation. 3. Regeneron announced a quarterly cash dividend and boosted its share buyback program. 4. Revenue rose 10% year-over-year, beating analyst estimates by $48 million. 5. Despite recent growth, stock is down 29% in the past year.